中文
 

Follow us 

Hot Topic
Market News
Events & Promo
Career Tips
Education News
Health & Life
Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment
PRNewswire

Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment

Publish date: 28 Oct 2026

Follow us

Stay updated on the job market

Popular Articles

【辦公室職業病】Office 工最易中嘅四大職場傷患!入嚟睇吓你有無中招(附預防自救法)
【辦公室職業病】Office 工最易中嘅四大職場傷患!入嚟睇吓你有無中招(附預防自救法)
【AI 衝擊打工仔】最新調查:逾半港人憂AI令退休前景更難預測!「飯碗不保」恐打破傳統退養規劃
【AI 衝擊打工仔】最新調查:逾半港人憂AI令退休前景更難預測!「飯碗不保」恐打破傳統退養規劃
【薪酬趨勢調查】本港僱員今年平均加薪 2.3%!預測明年升至 3.1%,增幅仍遜大灣區內地城市
【薪酬趨勢調查】本港僱員今年平均加薪 2.3%!預測明年升至 3.1%,增幅仍遜大灣區內地城市
【鐵飯碗神話幻滅?】護理畢業即失業!寄成百封 CV 零回音,香港護士正面臨大洗牌
【鐵飯碗神話幻滅?】護理畢業即失業!寄成百封 CV 零回音,香港護士正面臨大洗牌
【方大資訊日2026】首日吸引逾5,000人入場!聖方濟各大學拆解熱門課程入學攻略,應科大實務教學成焦點
【方大資訊日2026】首日吸引逾5,000人入場!聖方濟各大學拆解熱門課程入學攻略,應科大實務教學成焦點

SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and multidisciplinary expertise to serve patients from China and abroad.

The center was unveiled at the inaugural Jiahui International Cell Therapy Summit on October 23, hosted by Jiahui International Hospital and co-organized by Jiahui Medical Research & Education Group (J-Med). The event attracted livestream viewing registrations from 14 countries and regions.

Prof. HAO Siguo, Chief of Hematology at Jiahui International Cancer Center (JICC), and Prof. XUAN Linli, Chief of Medical Oncology at JICC, joined experts discussing cellular therapies for blood cancers, solid tumors and autoimmune diseases.

Eric J. Rubin, Editor-in-Chief of the New England Journal of Medicine (NEJM), noted that NEJM published one research article by Chinese scholars a decade ago, compared with more than 20 in 2026. Prof. John K. HSIANG, Chairman of Jiahui Health Executive Committee, highlighted China's advances in medical innovation.

JICC has established a track record of pioneering CAR-T treatments and encouraging long-term patient outcomes. In September 2023, JICC treated China's first international patient to receive axicabtagene ciloleucel (Axi-Cel) CAR-T therapy, a Singaporean woman with primary mediastinal large B-cell lymphoma, who remains relapse-free more than three years after treatment. Building on this milestone, JICC has provided CAR-T treatment to patients from Singapore, Hong Kong SAR, Russia, Hungary, New Zealand, India, Pakistan, the Maldives and other countries and regions. Following China's June 2026 approval of Satri-cel (CT041), the world's first CAR-T therapy approved for solid tumors, Jiahui became one of the first institutions to introduce it clinically and treated the world's first international recipient—a 59-year-old New Zealand patient with advanced gastroduodenal cancer.

Prof. Allen WU, President of Jiahui International Hospital, said growing international demand helped drive the center's launch. The hospital provides nearly 500,000 patient visits annually to people from 180 countries and regions. The new center will link research and clinical care through multidisciplinary expertise and international patient services.

Read the full story: https://jiahui.com/en/news/231

Contact Jiahui International Cancer Center:
Email: internationaloffice@jiahui.com
WhatsApp: +852 4619 1904
WeChat: Jiahui-GSN

Follow us

Stay updated on the job market

Popular Articles

【辦公室職業病】Office 工最易中嘅四大職場傷患!入嚟睇吓你有無中招(附預防自救法)
【辦公室職業病】Office 工最易中嘅四大職場傷患!入嚟睇吓你有無中招(附預防自救法)
【AI 衝擊打工仔】最新調查:逾半港人憂AI令退休前景更難預測!「飯碗不保」恐打破傳統退養規劃
【AI 衝擊打工仔】最新調查:逾半港人憂AI令退休前景更難預測!「飯碗不保」恐打破傳統退養規劃
【薪酬趨勢調查】本港僱員今年平均加薪 2.3%!預測明年升至 3.1%,增幅仍遜大灣區內地城市
【薪酬趨勢調查】本港僱員今年平均加薪 2.3%!預測明年升至 3.1%,增幅仍遜大灣區內地城市
【鐵飯碗神話幻滅?】護理畢業即失業!寄成百封 CV 零回音,香港護士正面臨大洗牌
【鐵飯碗神話幻滅?】護理畢業即失業!寄成百封 CV 零回音,香港護士正面臨大洗牌
【方大資訊日2026】首日吸引逾5,000人入場!聖方濟各大學拆解熱門課程入學攻略,應科大實務教學成焦點
【方大資訊日2026】首日吸引逾5,000人入場!聖方濟各大學拆解熱門課程入學攻略,應科大實務教學成焦點

Hottest Tags

#辦公室職業病
#打工仔勞損
#烏龜頸
#滑鼠手腕管綜合症
#腰背痛
#人體工學椅
#辦公室拉筋伸展
#乾眼症
#職場健康
#勞工處職業安全
#AI衝擊打工仔
#人工智能退休規劃

Contact Us
Notice
Back to Top
We use cookies to enhance your experience on our website. Please read and confirm your agreement to our Privacy Policy and Terms and Conditions before continue to browse our website. Read and Agreed